FiercePharmaOriginal article
{"a":[{"_":"ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM","$":{"href":"/biotech/esc-alnylams-next-gen-silencer-sees-silver-linings-after-fallout-az-ionis-trial-flop-attr","hreflang":"en"}}]}
Phase 3negativeWainuaAlnylam silencing drugsNegative
AI Analysis
Summary
AstraZeneca's Phase 3 trial of Wainua, developed with Ionis partner for ATTR-CM, has failed, though analysts suggest Alnylam's silencing drugs may still have potential in the same indication when combined with standard-of-care stabilizers.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 failure of AstraZeneca and Ionis-partnered Wainua in ATTR-CM
Importance:7/10
Sentiment:
-0.30
ATTR-CMPhase 3 failureRNA interferencegene silencingstandard-of-care combination
Read the original article
Published by FiercePharma on August 31, 2026 2:48 PM